Cancer Research and Treatment

Original Articles

Skin cancer

Incidence and Survival Rates of Cutaneous Melanoma in South Korea Using Nationwide Health Insurance Claims Data: TaeHo Kim, Siyeong Yoon, Dong-Eun Shin, Sang Cheol Lee, Jisu Oh, So-Young Lee, Do Kyung Kim, Segi Kim, Bosung Jung, Minsup Kim, Soonchul Lee; Cancer Res Treat. 2022;54(3):937-949. Published online September 30, 2021; DOI: https://doi.org/10.4143/crt.2021.871

Abstract PDF Supplementary Material PubReader ePub

Purpose
Melanoma incidence is rising worldwide along with the associated personal and socioeconomic health expenditures. We investigated the incidence and survival-rate patterns of melanoma in South Korea using nationwide data.
Materials and Methods
This retrospective cohort study included patients with melanoma between 2004 and 2017, based on National Health Insurance (NHI) claims data in South Korea. The incidence, prevalence, and survival rate were analyzed along with baseline demographic characteristics. We collected solar irradiation dose (SID) and healthcare ranking score (HRS) according to the administrative district from the Korea Meteorological Administration and Korea Health Promotion Institute. The incidence and survival rates were assessed using Pearson's correlation, the Kaplan-Meier estimation, multiple linear regression, and multiple logistic regression methods.
Results
Twenty-five thousand, five hundred ninety-one patients with melanoma were diagnosed during the study period. The age-standardized incidence of melanoma steadily increased from 2004 to 2017 from 2.6 to 3.0/100,000/yr. The incidence of melanoma increased with significantly higher income (p < 0.05). The prevalence followed a similar pattern as the incidence. According to multivariate analysis, HRS significantly influenced the incidence of melanoma in high sun-exposed sites (p < 0.001). There was no significant change in annual mortality. Women had a higher 5-year survival rate than men (78.4% vs. 72.8%). Mortality by the administrative district was highly correlated with HRS.
Conclusion
The incidence of melanoma is increasing in South Korea. A low HRS is associated with both higher incidence and mortality. The findings of this study could be utilized as a guideline for treating melanoma patients.

Citations

Citations to this article as recorded by

Risk of second primary malignancies among survivors of cutaneous melanoma: A nationwide population-based study in the Republic of Korea
Joon Min Jung, Do Hyung Kim, Ye-Jee Kim, Ik Jun Moon, Woo Jin Lee, Sung Eun Chang, Mi Woo Lee, Chong Hyun Won
Scientific Reports.2025;[Epub] CrossRef
Incidence and survival rates of primary cutaneous malignancies in Korea, 1999–2019: A nationwide population‐based study
Soon‐Hyo Kwon, Sangmin Choi, Joung Soo Kim, Sang Seok Kim, Mihn‐Sook Jue, Soo Hong Seo, Jihye Park, Mi Ryung Roh, Je‐Ho Mun, Jun Young Kim, Jee Woong Choi, Ji Won Byun, Sanghyun Park, Min Sung Kim, Seok‐Jong Lee
The Journal of Dermatology.2024; 51(4): 532. CrossRef
The Effect of Interval Training and Urtica Dioica Hydroalcoholic Extract on some Growth and Immune Factors in C57 Rats with Melanoma Cancer
Maryam Firoozi, Alireza Barari, Asieh Abbassi Daloii, Hossein Abednatanzi
Complementary Medicine Journal.2024; 13(4): 44. CrossRef
Hellebrigenin induces apoptosis by triggering cellular inhibitor of apoptosis 1 and Jun N-terminal kinase pathway in melanoma cells
Mu-Kuei Shieu, Yi-Ching Chuang, Hsin-Yu Ho, Chia-Chieh Lin, Yu-Sheng Lo, Ming-Ju Hsieh
Dermatologica Sinica.2024; 42(1): 19. CrossRef
Analyses of Osteogenesis Imperfecta in South Korea Using the Nationwide Health Insurance Service Claim Data: A Propensity Score-Matched Study
Sin Hyung Park, Ho Yoon, Siyeong Yoon, Jaiwoo Chung, Jae-hyun Kim, Soonchul Lee
Calcified Tissue International.2024; 115(6): 915. CrossRef
Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea
Isaac Kim, Jisu Oh, Siyeoung Yoon, Man-Yong Han, Jaiwoo Chung, Younghoon Jung, Hyun-Il Lee, Soonchul Lee
Melanoma Research.2024; 34(6): 528. CrossRef
FOXN3 Regulates Autophagic Activity to Suppress Drug Resistance in Melanoma Cells
Yaqi Wang, Hui Su, Xiaopeng Wang, Chen Tu, Tong Xiao, Bincheng Ren, Shuang Wang
Clinical, Cosmetic and Investigational Dermatology.2024; Volume 17: 2505. CrossRef
The effects of exposure to solar radiation on human health
R. E. Neale, R. M. Lucas, S. N. Byrne, L. Hollestein, L. E. Rhodes, S. Yazar, A. R. Young, M. Berwick, R. A. Ireland, C. M. Olsen
Photochemical & Photobiological Sciences.2023; 22(5): 1011. CrossRef
Survival rates for invasive cutaneous malignant melanoma in South Korea in accordance with the Eighth edition AJCC Cancer Staging Manual: A retrospective single center study
Seon Hwa Lee, Gi Ung Ha, Hyun Ji Lee, Ho Yun Chung, Seung Huh, Dae-Lyong Ha, Kyung Duck Park, Yong Hyun Jang, Weon Ju Lee, Seok-Jong Lee, Jun Young Kim
Indian Journal of Dermatology, Venereology and Leprology.2023; 90: 163. CrossRef
Clinicopathological characteristics and prognosis of Merkel cell carcinoma: a single-center retrospective study in Korea
Ik Jun Moon, Hyungmin Na, Hye Soo Cho, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Woo Jin Lee
Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10065. CrossRef

9,958 View
212 Download
9 Web of Science
10 Crossref

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea: Seung Hoon Beom, Jisu Oh, Tae-Yong Kim, Kyung-Hun Lee, Yaewon Yang, Koung Jin Suh, Hyeong-Gon Moon, Sae-Won Han, Do-Youn Oh, Wonshik Han, Tae-You Kim, Dong-Young Noh, Seock-Ah Im; Cancer Res Treat. 2017;49(2):454-463. Published online August 23, 2016; DOI: https://doi.org/10.4143/crt.2016.259

Abstract PDF PubReader ePub

Purpose
Letrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)–positive metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports of the clinical outcomes in Korean patients, although letrozole is widely used in practice. Therefore, this studywas conducted to affirm the efficacy and toxicities of letrozole in Korean patients.
Materials and Methods
This study retrospectively analyzed 84 HR-positive MBC patients who had been treated with letrozole from January 2001 to December 2012. Clinicopathological characteristics and treatment historywere extracted from medicalrecords. All patients received 2.5 mg letrozole once a day until there were disease progressions or unacceptable toxicity. Progression-free survival (PFS) was the primary endpoint, and secondary endpoints were overall survival (OS), objective response rate (ORR), and toxicity.
Results
The median age of the subjects was 59.3 years. Letrozole treatment resulted in a median PFS of 16.8 months (95% confidence interval [CI], 9.8 to 23.8) and a median OS of 56.4 months (95% CI, 38.1 to 74.7). The ORR was 36.9% for the 84 patients with measurable lesions. Multivariate analysis revealed symptomatic visceral disease (hazard ratio, 3.437; 95% CI, 1.576 to 7.495; p=0.002) and a disease-free interval ≤ 2 years (hazard ratio, 2.697; 95% CI, 1.262 to 5.762; p=0.010) were independently associated with shorter PFS. However, sensitivity to adjuvant hormone treatment was not related to PFS. Letrozole was generally well tolerated.
Conclusion
Letrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.

Citations

Citations to this article as recorded by

Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis
Josee-Lyne Ethier, Danielle N. Desautels, Eitan Amir, Helen MacKay
Gynecologic Oncology.2017; 147(1): 158. CrossRef

12,789 View
252 Download
1 Web of Science
1 Crossref

First
Prev
Page of 1
Next
Last

Search